(UroToday.com) In the plenary program of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Ana Aparicio discussed the potential for currently utilized treatments in advanced prostate cancer to drive a new resistant mutational phenotype within a session entitled “Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer.”